ImmunityBio: Piper Sandler raises target price to $16 from $12
IBRX•Piper Sandler raised its target price for ImmunityBio to $16 from $12.
Related News
Brookfield Renewable Partners delays unitholder meeting to Oct. 29, 2026
BEP•
Air Canada: National Bank of Canada cuts target price to C$37 from C$40
AC•
Biomea Fusion, Inc.: Piper Sandler cuts target price to $4 from $7
BMEA•
FormFactor CEO Mike Slessor reports sale of $1.39 million in common shares
FORM•
ImmunityBio: Jefferies raises target price to $14 from $12
IBRX•